
Nabriva Therapeutics plc NBRV
Quarterly report 2023-Q1
added 05-22-2023
Nabriva Therapeutics plc Depreciation & Amortization 2011-2026 | NBRV
Annual Depreciation & Amortization Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 217 K | 356 K | 417 K | 396 K | 510 K | 432 K | 233 K | 153 K | 166 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 510 K | 153 K | 320 K |
Quarterly Depreciation & Amortization Nabriva Therapeutics plc
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 K | - | 192 K | - | 78 K | - | 270 K | - | 99 K | - | 315 K | 209 K | 103 K | - | 162 K | 245 K | 125 K | - | 391 K | 262 K | 133 K | - | 295 K | 149 K | 76 K | - | 172 K | 99 K | 45 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 391 K | 21 K | 172 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
546 K | $ 0.8 | -4.39 % | $ 36.6 M | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Exelixis
EXEL
|
29.1 M | $ 45.87 | -5.81 % | $ 12.5 B | ||
|
Fortress Biotech
FBIO
|
403 K | $ 2.42 | -5.1 % | $ 67.5 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.16 | 3.14 % | $ 3.67 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
105 K | $ 3.15 | - | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.62 | 5.85 % | $ 5.96 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Genprex
GNPX
|
6.69 K | $ 0.87 | -2.77 % | $ 811 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 20.85 | -13.74 % | $ 2.65 B | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 52.01 | -5.57 % | $ 4.68 B | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.58 | -7.06 % | $ 420 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |